T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma-Reference-Cited by-同舟云学术

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

Published:2019-10-01 Issue:19 Volume:3 Page:2812-2815
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Garfall Alfred L.¹^ORCID,Dancy Ehren K.²,Cohen Adam D.¹^ORCID,Hwang Wei-Ting³^ORCID,Fraietta Joseph A.⁴⁵⁶,Davis Megan M.⁵⁶^ORCID,Levine Bruce L.⁵⁶^ORCID,Siegel Don L.⁵⁶,Stadtmauer Edward A.¹,Vogl Dan T.¹^ORCID,Waxman Adam¹,Rapoport Aaron P.⁷,Milone Michael C.⁵⁶,June Carl H.⁵⁶,Melenhorst J. Joseph⁵⁶

Affiliation:

1. Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center,

2. Department of Medicine,

3. Department of Biostatistics, Epidemiology and Informatics, Abramson Cancer Center,

4. Department of Microbiology,

5. Department of Pathology and Laboratory Medicine, and

6. Center for Cellular Immunotherapies, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and

7. University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

Abstract

Key points T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/19/2812/1223943/advancesadv2019000600.pdf

Reference12 articles.

1. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma;Ali;Blood,2016

2. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma;Brudno;J Clin Oncol,2018

3. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma;Cohen;J Clin Invest,2019

4. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma;Raje;N Engl J Med,2019

5. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia;Fraietta;Nat Med,2018

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

3. CD4+ T cells in antitumor immunity;Trends in Cancer;2024-09

4. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience;Transplantation and Cellular Therapy;2024-08

5. Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma;Blood Advances;2024-07-31